Rating Change
Canaccord Genuity analysts reiterated a Buy rating on Stoke Therapeutics, Inc. (NASDAQ:STOK) on August 04, 2026.
reiterateNASDAQ:STOK
Canaccord Genuity Reiterates Buy Rating on Stoke Therapeutics, Inc. (STOK)
Rating Change Canaccord Genuity analysts reiterated a Buy rating on Stoke Therapeutics, Inc. (NASDAQ:STOK) on August 04, 2026. Market Context Stoke Therapeutics, Inc.
Market Context
Stoke Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $32.37 with a market capitalization of $1.9B.
Analyst coverage from Canaccord Genuity provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Stoke Therapeutics, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Stoke Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 04, 2026 | Guggenheim | Buy | N/A |
| Aug 04, 2026 | Wedbush | Outperform | N/A |
| Aug 04, 2026 | Canaccord Genuity | Buy | N/A |
| Aug 04, 2026 | Chardan Capital | Buy | N/A |
| Jul 13, 2026 | Goldman Sachs | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View STOK Stock Page
Frequently Asked Questions
What does a Buy rating mean for STOK?
A Buy rating from Canaccord Genuity reflects the analyst's outlook on Stoke Therapeutics, Inc. (NASDAQ:STOK). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the STOK forecast page.